Research programme: haemostasis therapy - Haemostatix

Drug Profile

Research programme: haemostasis therapy - Haemostatix

Alternative Names: HaemoPlax; HXTC-901; Systemic haemostat - Haemostatix

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Haemostatix
  • Class Albumins; Peptides
  • Mechanism of Action Fibrin stimulants; Fibrinogen modulators; Platelet aggregation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Surgical blood loss; Thrombocytopenia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Thrombocytopenia in United Kingdom (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for research development in Surgical-blood-loss(Prevention) in United Kingdom (IV, Infusion)
  • 06 Aug 2014 Early research in prevention of Surgical blood loss is ongoing in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top